此应用程序的某些内容目前无法使用。
如果这种情况持续存在,请联系我们反馈与联系
1. (WO2018138106) METHODS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF HEART FAILURE
注:相关文本通过自动光符识别流程生成。凡涉及法律问题,请以 PDF 版本为准

CLAIMS:

I . A method of treating heart failure in a subject in need thereof comprising administering to the subject a therapeutically effective amount of a PIKfyve inhibitor.

2. The method of claim 1 wherein the PIKfyve inhibitor is a small organic molecule.

3. The method of claim 1 wherein the PIKfyve inhibitor is selected from the group consisting of STA-5326, YM201636, APY0201, vacuolin-1, AS2677131 or AS2795440.

4. The method of claim 1 wherein the PIKfyve inhibitor is an aptamer.

5. The method according to claim 1 wherein the PIKfyve inhibitor is an inhibitor of PIKfyve expression.

6. The method according to claim 1 wherein the PIKfyve inhibitor is an antisense oligonucleotide.

7. The method according to claim 1 wherein the PIKfyve inhibitor is small inhibitory RNAs.

8. The method according to claim 1 wherein the PIKfyve inhibitor is a ribozyme.

9. The method according to claim 1, wherein the heart failure is associated with metabolic diseases.

10. The method according to claim 1, wherein the heart failure is associated with high blood pressure.

I I . The method according to claim 1 , wherein the heart failure is associated with coronary artery disease or heart attack.

12. The method according to any of the preceding claims wherein the PIKfyve inhibitor is administered to the subject in combination with a standard treatment.